U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H19F3N2S.ClH
Molecular Weight 388.878
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRIFLUPROMAZINE HYDROCHLORIDE

SMILES

Cl.CN(C)CCCN1C2=CC=CC=C2SC3=CC=C(C=C13)C(F)(F)F

InChI

InChIKey=FTNWXGFYRHWUKG-UHFFFAOYSA-N
InChI=1S/C18H19F3N2S.ClH/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21;/h3-4,6-9,12H,5,10-11H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H19F3N2S
Molecular Weight 352.417
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Triflupromazine is antipsychotic and an antiemetic drug (sold under the brand names VESPRIN) which used to management of psychoses. However, this drug was discontinued. Triflupromazine binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. Moreover, binds the muscarinic acetylcholine receptors (M1 and M2).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P11229
Gene ID: 1128.0
Gene Symbol: CHRM1
Target Organism: Homo sapiens (Human)
Target ID: P08172
Gene ID: 1129.0
Gene Symbol: CHRM2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VESPRIN

Approved Use

Used mainly in the management of psychoses. Also used to control nausea and vomiting

Launch Date

1957
Doses

Doses

DosePopulationAdverse events​
800 mg 1 times / day multiple, oral
Overdose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
unhealthy
150 mg 1 times / day multiple, intramuscular
Recommended
Dose: 150 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
unhealthy
3 mg 1 times / day multiple, intravenous
Recommended
Dose: 3 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 3 mg, 1 times / day
Sources:
unhealthy
PubMed

PubMed

TitleDatePubMed
Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes.
2013-06
The identification of inhibitors of Schistosoma mansoni miracidial transformation by incorporating a medium-throughput small-molecule screen.
2010-06
Molecularly imprinted polymers as analyte sequesters and selective surfaces for easy ambient sonic-spray ionization.
2010-04
Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology.
2010-03-03
Phenothiazine-type antipsychotics elicit cutaneous analgesia in rats.
2010-03
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle.
2010-02-23
Experimental analyses of synergistic combinations of antibiotics with a recently recognised antibacterial agent, lacidipine.
2010-02
Research on antipsychotics in India.
2010-01
Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.
2009-12
Effects of chemical manipulation of mitotic arrest and slippage on cancer cell survival and proliferation.
2009-09-15
Inhibitors of clathrin-dependent endocytosis enhance TGFbeta signaling and responses.
2009-06-01
Rapid method for the determination of tranquilizers and a beta-blocker in porcine and bovine kidney by liquid chromatography with tandem mass spectrometry.
2009-04-01
The effect of calmodulin antagonists on experimental scoliosis: a pinealectomized chicken model.
2009-03-15
Simultaneous determination of some phenothiazine derivatives in human blood by headspace solid-phase microextraction and gas chromatography with nitrogen-phosphorus detection.
2009-02-11
Analytical Applications of Reactions of Iron(III) and Hexacyanoferrate(III) with 2,10-Disubstituted Phenothiazines.
2009
Monitoring the (photo)genotoxicity of photosensitizer drugs: direct quantitation of single-strand breaks in deoxyribonucleic acid using an oligonucleotide chip.
2008-11-01
Energetics of binding and protein unfolding upon amphiphilic drug complexation with a globular protein in different aqueous media.
2008-06-01
Modification of the thermal unfolding pathways of myoglobin upon drug interaction in different aqueous media.
2007-12-13
[Derivative spectrophotometric and NMR spectroscopic study in pharmaceutical science].
2007-10
Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives.
2007-03-01
Trypanosoma cruzi dihydrolipoamide dehydrogenase as target for phenothiazine cationic radicals. Effect of antioxidants.
2006-09
Effects of inorganic ions on the binding of triflupromazine and chlorpromazine to bovine serum albumin studied by spectrometric methods.
2006-07
A kinetic study on the phenothiazine dependent oxidation of NADH by bovine ceruloplasmin.
2006-02
Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials.
2005-10-17
Effects of phosphatidylserine and phosphatidylethanolamine content on partitioning of triflupromazine and chlorpromazine between phosphatidylcholine-aminophospholipid bilayer vesicles and water studied by second-derivative spectrophotometry.
2005-01
Romifidine-ketamine anaesthesia in atropine and triflupromazine pre-medicated buffalo calves.
2004-12
19F NMR spectroscopic study on the binding of triflupromazine to bovine and human serum albumins.
2004-10-29
Dissociation constants of phenothiazine drugs incorporated in phosphatidylcholine bilayer of small unilamellar vesicles as determined by carbon-13 nuclear magnetic resonance spectrometric titration.
2004-02-10
Triflupromazine: a microbicide non-antibiotic compound.
2004
Trans-cellular proliferating cell nuclear antigen gene activation in cerebral vascular smooth muscle by endothelial oxidative injury in vivo.
2003-11-01
Thermodynamics of partitioning of phenothiazine drugs between phosphatidylcholine bilayer vesicles and water studied by second-derivative spectrophotometry.
2003-09
Inactivation of cholinesterase induced by chlorpromazine cation radicals.
2003-02
Partition of N-monodemethylated phenothiazine drugs to phosphatidylcholine bilayer vesicles studied by second-derivative spectrophotometry.
2002-06
Interaction of protonated anticancer thiazines with water-insoluble phospholipids and antineoplastic agents.
2002-05-17
Activation of Maxi Cl(-) channels by antiestrogens and phenothiazines in NIH3T3 fibroblasts.
2002-05
[Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo].
2001-07
Aluminum balance in intensive care patients.
2001-04
Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes.
1984-09
[Four cases of extrapyramidal effects following the treatment of hyperemesis gravidarum with triflupromazin (author's transl)].
1976-04
A case report of akathisia due to triflupromazine.
1971-04
Patents

Sample Use Guides

Unknown
Route of Administration: Intramuscular
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:27:37 GMT 2025
Edited
by admin
on Mon Mar 31 21:27:37 GMT 2025
Record UNII
9E75N4A5HM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRIFLUPROMAZINE HYDROCHLORIDE
GREEN BOOK   JAN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
Common Name English
MC-4703
Preferred Name English
TRIFLUPROMAZINE HCL
Common Name English
TRIFLUPROMAZINE HYDROCHLORIDE [VANDF]
Common Name English
TRIFLUPROMAZINE HYDROCHLORIDE [GREEN BOOK]
Common Name English
NSC-14959
Code English
TRIFLUPROMAZINE HYDROCHLORIDE [MART.]
Common Name English
10-[3-(Dimethylamino)propyl]-2-(trifluoromethyl)phenothiazine monohydrochloride
Systematic Name English
TRIFLUPROMAZINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
TRIFLUPROMAZINE HYDROCHLORIDE [JAN]
Common Name English
NSC-17473
Code English
TRIFLUPROMAZINE HYDROCHLORIDE [MI]
Common Name English
TRIFLUPROMAZINE HYDROCHLORIDE [USP-RS]
Common Name English
Triflupromazine hydrochloride [WHO-DD]
Common Name English
TRIFLUPROMAZINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
10H-PHENOTHIAZINE-10-PROPANAMINE, N,N-DIMETHYL-2-(TRIFLUOROMETHYL)-, MONOHYDROCHLORIDE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C740
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
CFR 21 CFR 522.2582
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
NCI_THESAURUS C29710
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C66636
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
NSC
14959
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
RS_ITEM_NUM
1686003
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
ChEMBL
CHEMBL570
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
FDA UNII
9E75N4A5HM
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
EVMPD
SUB04958MIG
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
RXCUI
91125
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY RxNorm
ECHA (EC/EINECS)
214-149-6
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
MERCK INDEX
m11123
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY Merck Index
NSC
17473
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
CAS
1098-60-8
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
EPA CompTox
DTXSID8045804
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
SMS_ID
100000084644
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
PUBCHEM
66069
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
DRUG BANK
DBSALT001039
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
CHEBI
9712
Created by admin on Mon Mar 31 21:27:37 GMT 2025 , Edited by admin on Mon Mar 31 21:27:37 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY